Telangana: Five hospitals get notices for violating norms

Medical Dialogues team had earlier reported about a similar incident where an announcement had been made by the Pharma major, Lupin stating that the Company had received a warning letter from the US Food and Drug Administration (USFDA) for the Company's Tarapur, Maharashtra (India) facility. The USFDA inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022. In their BSE filing, the ccompany sgtated, "The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility."  It also noted that they are committed to addressing the concerns raised by the U.S. FDA and would work with the U.S. FDA to resolve these issues at the earliest. They observed, "We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities." 

Also Read:USFDA inspection: Lupin gets warning letter for Tarapur facility